Somewhat Positive Press Coverage Somewhat Unlikely to Affect Voyager Therapeutics (VYGR) Stock Price

News stories about Voyager Therapeutics (NASDAQ:VYGR) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Voyager Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.297259361899 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of VYGR traded up $0.06 during mid-day trading on Thursday, hitting $19.56. 101,026 shares of the company’s stock were exchanged, compared to its average volume of 435,756. Voyager Therapeutics has a 52 week low of $8.10 and a 52 week high of $31.91. The stock has a market capitalization of $619.34, a PE ratio of -7.41 and a beta of 2.97.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, March 14th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative net margin of 697.03% and a negative return on equity of 63.18%. The company had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $5.81 million. sell-side analysts forecast that Voyager Therapeutics will post -2.54 EPS for the current year.



VYGR has been the subject of several research reports. BidaskClub downgraded shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. BTIG Research began coverage on shares of Voyager Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $26.00 target price on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. Piper Jaffray reaffirmed a “buy” rating and set a $40.00 target price on shares of Voyager Therapeutics in a report on Monday, March 12th. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Friday, March 16th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $29.73.

In related news, insider Bernard Ravina sold 2,451 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $18.24, for a total value of $44,706.24. Following the transaction, the insider now directly owns 4,902 shares of the company’s stock, valued at $89,412.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dinah Ph.D. Sah sold 15,623 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total transaction of $468,690.00. Following the completion of the transaction, the insider now directly owns 140,872 shares in the company, valued at $4,226,160. The disclosure for this sale can be found here. Insiders have sold 64,457 shares of company stock worth $1,529,209 over the last ninety days. Insiders own 8.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Voyager Therapeutics (VYGR) Stock Price” was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-voyager-therapeutics-vygr-stock-price.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply